The current results strengthen the rationale for future validation of ApoA-I-mimetic peptides (such as L-4F), which may serve as adjuvant therapeutic agents for the treatment of pancreatic cancer. The gene discussed is APOA1; the disease is familial pancreatic carcinoma.